508 related articles for article (PubMed ID: 30730407)
21. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
22. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
Flaig TW
J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
[TBL] [Abstract][Full Text] [Related]
23. An update on immunotherapy options for urothelial cancer.
Bilgin B; Sendur MAN; Hizal M; Yalçın B
Expert Opin Biol Ther; 2019 Dec; 19(12):1265-1274. PubMed ID: 31518156
[No Abstract] [Full Text] [Related]
24. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
[TBL] [Abstract][Full Text] [Related]
25. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
26. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.
Nassar AH; Mouw KW; Jegede O; Shinagare AB; Kim J; Liu CJ; Pomerantz M; Harshman LC; Van Allen EM; Wei XX; McGregor B; Choudhury AD; Preston MA; Dong F; Signoretti S; Lindeman NI; Bellmunt J; Choueiri TK; Sonpavde G; Kwiatkowski DJ
Br J Cancer; 2020 Feb; 122(4):555-563. PubMed ID: 31857723
[TBL] [Abstract][Full Text] [Related]
27. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
28. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
29. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Yuen KC; Liu LF; Gupta V; Madireddi S; Keerthivasan S; Li C; Rishipathak D; Williams P; Kadel EE; Koeppen H; Chen YJ; Modrusan Z; Grogan JL; Banchereau R; Leng N; Thastrom A; Shen X; Hashimoto K; Tayama D; van der Heijden MS; Rosenberg JE; McDermott DF; Powles T; Hegde PS; Huseni MA; Mariathasan S
Nat Med; 2020 May; 26(5):693-698. PubMed ID: 32405063
[TBL] [Abstract][Full Text] [Related]
30. Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma.
Ghatalia P; Plimack ER
J Natl Compr Canc Netw; 2020 Mar; 18(3):355-361. PubMed ID: 32135514
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Smyth E; Thuss-Patience PC
Oncol Res Treat; 2018; 41(5):272-280. PubMed ID: 29705787
[TBL] [Abstract][Full Text] [Related]
32. PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Hsu MM; Balar AV
Clin Genitourin Cancer; 2019 Jun; 17(3):e618-e626. PubMed ID: 31005473
[TBL] [Abstract][Full Text] [Related]
33. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma.
Weiss J; Notohamiprodjo M; Bedke J; Nikolaou K; Kaufmann S
Curr Opin Urol; 2018 Jan; 28(1):35-41. PubMed ID: 29083998
[TBL] [Abstract][Full Text] [Related]
34. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
Grimm MO; Bex A; De Santis M; Ljungberg B; Catto JWF; Rouprêt M; Hussain SA; Bellmunt J; Powles T; Wirth M; Van Poppel H
Eur Urol; 2019 Sep; 76(3):368-380. PubMed ID: 31235192
[TBL] [Abstract][Full Text] [Related]
35. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
36. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
Liu H; Ye T; Yang X; Lv P; Wu X; Zhou H; Lu H; Tang K; Ye Z
Dis Markers; 2020; 2020():8375348. PubMed ID: 32685057
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab for the treatment of urothelial cancers.
Teo MY; Rosenberg JE
Expert Rev Anticancer Ther; 2018 Mar; 18(3):215-221. PubMed ID: 29363363
[TBL] [Abstract][Full Text] [Related]
38. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Powles T; Carroll D; Chowdhury S; Gravis G; Joly F; Carles J; Fléchon A; Maroto P; Petrylak D; Rolland F; Cook N; Balar AV; Sridhar SS; Galsky MD; Grivas P; Ravaud A; Jones R; Cosaert J; Hodgson D; Kozarewa I; Mather R; McEwen R; Mercier F; Landers D
Nat Med; 2021 May; 27(5):793-801. PubMed ID: 33941921
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
